Previous Close | 19.65 |
Open | 19.37 |
Bid | 19.11 x 1400 |
Ask | 20.82 x 1300 |
Day's Range | 19.02 - 20.00 |
52 Week Range | 7.39 - 28.40 |
Volume | |
Avg. Volume | 622,267 |
Market Cap | 3.316B |
Beta (5Y Monthly) | 0.89 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.23 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.46 |
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2022 on Tuesday, February 28, 2023 at 3:30 am Eastern Standard Time (EST) / 8:30 am Greenwich Mean Time (GMT) / 4:30 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.
— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Europe and Japan planned to complete in 2023 — — Partnership approach aligned with HUTCHMED’s path to profitability and strategy to bring its innovative medicines to patients worldwide — — HUTCHMED to host a conference call and webcast at 8:30 a.m. EST (1:30 p.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS® (savolitinib) has been included in the updated National Reimbursement Drug List (“NRDL”) for the treatment of locally advanced or metastatic non-small cell lung cancer (“NSCLC”) adult patients with MET exon 14-skipping alterations who